发明名称 |
Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1(MTM1) polypeptides |
摘要 |
The present invention provides chimeric polypeptides comprising myotubularin 1 (MTMI) polypeptides and an internalizing moiety, wherein, the moiety can be an antibody, and is preferably monoclonal antibody 3E10, a functional variant or a fragment thereof. One aspect of the present invention provides compositions comprising these chimeric polypeptides together with a pharmaceutically acceptable carrier, and optionally, a further therapeutic agent. Another aspect of the present invention provides methods of treating Myotubular Myopathy comprising administering the polypeptides or compositions comprising the polypeptides to a subject in need. |
申请公布号 |
US9447394(B2) |
申请公布日期 |
2016.09.20 |
申请号 |
US201414485524 |
申请日期 |
2014.09.12 |
申请人 |
Valerion Therapeutics, LLC |
发明人 |
Armstrong Dustin D. |
分类号 |
C07K16/28;C12N9/00;C12N9/16;A61K47/48;C07K16/44;A61K38/00;A61K39/00 |
主分类号 |
C07K16/28 |
代理机构 |
Ropes & Gray LLP |
代理人 |
Ropes & Gray LLP |
主权项 |
1. A chimeric polypeptide comprising: (i) a myotubularin (MTM1) polypeptide, or a bioactive fragment thereof; wherein the MTM1 polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1, and (ii) an internalizing moiety,
wherein the chimeric polypeptide has phosphoinositide phosphatase activity; wherein said internalizing moiety is an antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment thereof is a monoclonal antibody 3E10, or a variant thereof that retains the cell penetrating activity of 3E10, or an antigen-binding fragment of any of the foregoing. |
地址 |
Concord MA US |